Clinical Trials Logo

Filter by:
NCT ID: NCT05594784 Recruiting - Clinical trials for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Start date: October 8, 2022
Phase: Phase 2
Study type: Interventional

The introduction of TKIs has greatly improved the prognosis of Ph+ ALL patients. The third-generation TKI ponatinib in combination with chemotherapy has demonstrated superior efficacy to first- and second-generation TKIs. However, unfortunately, ponatinib is not available in mainland China. Olverembatinib is the only third-generation TKI drug currently approved in mainland China. Venetoclax is an oral selective inhibitor of Bcl-2, and small exploratory clinical studies have demonstrated that venetoclax in combination with ponatinib showed high rates of CR as well as molecular response in relapsed/refractory Ph+ ALL. This study will explore the safety and efficacy of olverembatinib in combination with reduced-intensity chemotherapy and venetoclax in patients with newly diagnosed Ph+ ALL.

NCT ID: NCT05594719 Recruiting - Myopia Clinical Trials

The Effect of Sun-like Spectrum With Different Spectrum Composition on Retinal Blood Flow

Start date: September 6, 2022
Phase: N/A
Study type: Interventional

In 2020, the overall myopia rate among children and adolescents was 52.7% in China. The COVID-19 pandemic has increased students' time of indoor eye-using, and it showed that the light exposure intensity of myopic students is lower than that of non-myopia students. Studies have found that in addition to exposure to light intensity, the occurrence and development of myopia is also related to the color temperature and wavelength band of light. The sun-like spectrum refers to the spectrum with continuous wavelength bands. Animal experiments suggest that sun-like artificial lighting can prevent myopia, but the relationship between sun-like artificial lighting with different color temperatures and myopia is unknown. Clinical trials suggest that artificial lighting with a sun-like spectrum can delay fundus blood flow decline. One hypothesis is that reduced choroidal blood flow leads to scleral hypoxia and promotes the development of myopia. This study aims at comparing the effects of sun-like spectrum artificial lighting with different dominant wavelengths on the human eye, and providing clues for the prevention and control of myopia.

NCT ID: NCT05594095 Recruiting - Breast Cancer Clinical Trials

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Start date: December 30, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.

NCT ID: NCT05593627 Recruiting - Heart Valve Surgery Clinical Trials

Effect of Lithium Carbonate on Postoperative Sleep and Cognitive Function in Patients Undergoing Heart Valve Surgery With Cardiopulmonary Bypass

Start date: July 1, 2023
Phase: Phase 4
Study type: Interventional

It has been proved that lithium carbonate can prolong slow wave sleep with few or no side-effects. The aim of the present study is to evaluate postoperative sleep quality of patients undergoing heart valve surgery with cardiopulmonary bypass taken 250mg lithium carbonate after surgery.

NCT ID: NCT05593575 Recruiting - Clinical trials for Diabetic Kidney Disease

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Start date: March 22, 2023
Phase: Phase 2
Study type: Interventional

To preliminarily evaluate the efficacy and safety of the renin inhibitor (SPH3127 tablets) in reduction in proteinuria in patients with diabetic kidney disease with valsartan as the comparator, and determine the recommended dose.

NCT ID: NCT05593458 Recruiting - Clinical trials for Locally Advanced Gastric Carcinoma

Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1

TACTIC
Start date: April 1, 2023
Phase: Phase 3
Study type: Interventional

SOX regimen, consisting of oral S-1 and intravenous oxaliplatin, is the preferred regimen for perioperative chemotherapy for gastric cancer. The goal of this clinical trial is to compare the efficacy and safety between S-1 combined with oxaliplatin by arterial infusion, as neoadjuvant chemotherapy, and conventional SOX regimen, in locally advanced gastric cancer. The main question it aims to answer is: whether arterially infused oxaliplatin plus S-1 has the potential to be a better neoadjuvant option for patients with locally advanced gastric cancer. Participants will be randomised, and receive: - 3 cycles of conventional SOX chemotherapy plus PD-1 antibody or arterial infused oxaliplatin plus S-1 and PD-1 antibody, as neoadjuvant chemotherapy; - Adequate gastric resection along with D2 lymph node dissection; - 3 cycles adjuvant chemotherapy using SOX regimen plus PD-1 antibody. - Administration of S-1 regularly till 1 year after surgery. Researchers will compare Major pathological response rate (MPR) ,pathologic complete response rate(pCR),the 2-year overall survival (OS) rates, 2-year disease free survival (DFS), R0 resection rates, and adverse events, to see if the modified perioperative chemotherapy improve the prognosis of patients with locally advanced gastric cancer.

NCT ID: NCT05593419 Recruiting - Clinical trials for Gastric Cancer Patients Received Immunotherapy

Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers.

Start date: October 31, 2022
Phase:
Study type: Observational

We have established a machine learning model based on effective TIIC signature which could select GC patients who may benefit from immunotherapy. The current study aims to enroll 300 GC patients as a validation cohort to vertify the accuracy of TIIC signature in predicting immunotherapy efficacy

NCT ID: NCT05593367 Recruiting - Clinical trials for Diarrhea-predominant Irritable Bowel Syndrome

Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients

Start date: February 1, 2022
Phase:
Study type: Observational

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease. Evidence suggests that the concentration of serum VD is decreased in IBS patients, particularly in IBS-D. After giving a supplementation of VD, some symptoms of these patients were relieved to a certain degree. However, the specific mechanism still remains unclear.

NCT ID: NCT05593146 Recruiting - Clinical trials for Periacetabular Tumor

A Randomized Controlled Study Evaluating Modified Cup Anteversion Placement in Prevention of Postoperative Dislocation in Patients Undergoing Acetabular Tumor Resection and Reconstruction

Start date: April 13, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this clinical study is to investigate whether patients who receive modified anteversion angle (( α-15°)±10°) of the acetabular cup have a lower risk of dislocation within one year after surgery, compared to patients who receive conventional anteversion angle ( α±10°) of the acetabular cup. The hypothesis is that patients with placement of the modified (( α-15°)±10°) anteversion angle of the acetabular component will have decreased risk of dislocation 1 year after surgery compared to patients with conventional anteversion angle ( α±10°) placement. PS: α refers to the preoperative anteversion angle of the affected hip. α equals to the anteversion angle of the contralateral limb if it cannot be accurately measured on the affected limb. A standard error within 10° is accepted

NCT ID: NCT05593120 Recruiting - Clinical trials for Coronary Artery Disease

Evaluation of Health Economics for Noninvasive Coronary Fractional Flow Reserve Measurement Technology

Start date: June 29, 2022
Phase:
Study type: Observational

To determine whether, in a Chinese population of patients presenting to Wuhan Asia Heart Hospital, Fractional Flow Reserve Derived from Coronary Computed Tomography Angiography (CT-FFR) as a default test is noninferior in terms of total costs when compared to routine clinical pathway recommended by the investigator and the institution's heart team.